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ABSTRACT 
Symptoms of osteoarthritis (OA) afflict approximately 20% of adult dogs in North 
America. Clinical signs consistent with OA include decreased range of motion of a joint, reduced 
physical activity, difficulty climbing stairs or onto furniture, and a reduced ability to rise from a 
lying position. A safe and effective nutraceutical supplement may benefit dogs suffering from 
OA. Calcium fructoborate (CFB), a mimetic of a naturally occurring molecule, has previously 
been reported to be safe and effective in humans with joint problems. The objective of this 
randomized, double-blinded, placebo-controlled study was to evaluate the short-term effects of 
CFB alone, or in combination with a blend of glucosamine hydrochloride (GH) and chondroitin 
sulfate (CS), on gait analysis, goniometry, serum inflammatory markers, and owner perception of 
pain in client-owned dogs. Sixty-four dogs with joint discomfort were recruited and 59 dogs 
(mean age = 8.42 ± 0.37 yr.; mean BW = 31.11 ± 1.28 kg) completed the study. All procedures 
were approved by the University of Illinois Institutional Animal Care and Use Committee, and 
pet owners signed an informed consent prior to study initiation. Dogs were randomly assigned to 
one of four treatments: placebo (60 mg fructose; n = 15), low dose (69 mg CFB; n = 14), high 
dose (127 mg CFB; n = 14), or combination (69 mg CFB, 500 mg GH and 200 mg CS; n = 16). 
Treatments were provided once daily as dietary supplements. Small dogs weighing up to 22.9 kg 
received 1 capsule/day, while large dogs weighing 23 to 50 kg received 2 capsules/day for 28 
days. A physical examination, radiographs, goniometry measurements, gait analysis, blood 
sample collection, and the canine brief pain inventory (CBPI) questionnaire were performed and 
administered on days 0 and 28. As expected, a majority (69%) of the dogs were overweight or 
obese, with a body condition score (BCS) > 6 on a 9-point scale. Dogs fed the low dose (-2.93) 
and high dose (-2.21) of CFB were shown to improve (P < 0.05) in their ability to rise from a 
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lying position from day 0 to day 28 compared to dogs fed the placebo (0.00), but no difference 
was observed for dogs fed the combination treatment. Dogs assigned the low dose of CFB also 
tended to have an improved pain severity score (PSS; -1.46; P = 0.08) and pain at its worst score 
(-2.14; P = 0.06) from day 0 to day 28 compared to dogs fed the placebo (0.05 and 0.00, 
respectively). Dogs fed the high dose of CFB had a greater increase (P = 0.05) in serum 
concentration of soluble receptor for advanced glycation end products (sRAGE) from day 0 to 
day 28 (7.88 ng/mL) compared to dogs fed the placebo (0.83 ng/mL). All blood metabolites were 
within reference range except total alkaline phosphatase and corticosteroid-induced alkaline 
phosphatase, which started and ended at concentrations greater than the upper reference range. 
Dogs assigned the high dose of CFB tended to have a greater reduction (P = 0.07) in serum 
chloride from day 0 to day 28 (-1.64 mmol/L) compared to dogs fed the low dose of CFB (0.08 
mmol/L). Given the low number of small dogs recruited and the increased variability noted as a 
result of their inclusion, a sub-analysis of large dogs only was performed. Large dogs fed the low 
dose were shown to have decreased (P < 0.05) scores for PSS (-1.77) and pain at its worst (-2.45) 
from day 0 to day 28 compared to the placebo group (0.19 and 0.42, respectively). Large dogs 
assigned the low dose of CFB tended to have improved scores for pain at its least (-1.27; P = 
0.08) and pain on average (-1.82; P = 0.07) from day 0 to day 28 compared to dogs fed the 
placebo (0.25 and -0.08, respectively), but no difference was observed for dogs fed the high dose 
or combination groups. Large dogs fed the low dose also were shown to improve (P < 0.05) in 
their ability to rise from a lying position (-3.09) compared to the placebo treatment (0.25) from 
day 0 to day 28. Overall, supplementation of CFB alone was well-tolerated and appeared to have 
potential for joint discomfort mitigation in canines. 
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Chapter 1 
Introduction 
Classifying pets as members of the family is a growing trend in the United States. In 
2011, 63.2% of owners viewed their pets as members of the family (American Veterinary 
Medical Association, 2012). With that trend, a pet’s health, lifespan, and quality of life (QOL) 
have become increasingly important to owners. The American Pet Products Association reported 
that 65% of the households in the United States own a pet, including a population of over 77 
million dogs (American Pet Products Association, 2015). As man’s best friend, owners closely 
monitor their dogs and will go to great lengths to maintain health and avoid pain.  
Osteoarthritis (OA), also known as degenerative joint disease or osteoarthrosis, is a 
debilitating, irreversible, lifelong disease that has no cure. In North America, over 20% of dogs 
over the age of 1 suffer from OA (Johnston, 1997). Based on the results of a lifelong study 
conducted on Labrador Retrievers that noted a linear development of OA with age, the incidence 
in aged dogs is much greater (Smith et al., 2006). Therefore, the prevalence of OA is even higher 
in geriatric dogs. Osteoarthritis affects mainly the hips, elbows, and stifles of dogs, but also can 
cause problems in vertebral, carpal, and tarsal joints. Common clinical signs include pain, 
tenderness, decreased range of motion (ROM), swelling, stiffness, muscle atrophy, crepitus, and 
effusion. Due to the pain and other symptoms, an affected dog’s behavior may change and lead 
to aggression, decreased activity, limping, problems rising from a lying position, and difficulty 
climbing stairs or onto furniture. Age is the main risk factor of OA, but other predisposing 
factors include genetics, size of the breed, obesity, joint deformity, trauma and fractures, surgery, 
and elbow or hip dysplasia (MacPhail, 2000; Rychel, 2010; Sandell, 2012).  
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Although there is no cure for OA, modalities exist such that the disease may be managed, 
resulting in slowed progression and decreased pain and signs associated with the disease. 
Treatment of OA aims to improve QOL of the animal by relieving pain, decreasing 
inflammation, increasing activity level, and increasing ROM of the joint (MacPhail, 2000). 
Nutraceuticals, food or dietary supplements that offer a health or medical benefit have become 
popular treatments for OA. Some treatments already exist, but novel nutraceuticals are being 
sought by the industry. Calcium fructoborate (CFB) is a naturally-occurring plant-mineral 
complex found in certain fruits, nuts, and legumes. It is commercially manufactured from a 
proprietary reaction of fructose, calcium, and boric acid that produces a nature-identical 
molecule composed of calcium bound to mono- and di-fructoborate complexes. Calcium 
fructoborate has been shown to positively affect humans suffering from symptoms of OA in 
several clinical studies, but has yet to be tested in dogs. Therefore, the objective of this study was 
to evaluate the short-term effects of CFB alone, or in combination with a blend of glucosamine 
hydrochloride (GH) and chondroitin sulfate (CS), on serum inflammatory markers, goniometry, 
gait analysis, and owner perception of pain in client-owned dogs. It was hypothesized that the 
CFB treatment would improve joint mobility, decrease pain, and decrease inflammatory markers.  
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Chapter 2 
 
Literature Review 
DOG POPULATION AND INCIDENCE OF OSTEOARTHRITIS 
 
The American Pet Products Association reported that 65% of the households in the 
United States own a pet, including a population of over 77 million dogs (American Pet Products 
Association, 2015). In 2011, 63.2% of owners classified their animals as members of the family 
(American Veterinary Medical Association, 2012). Because of that classification, a pet’s health, 
in addition to their length and quality of life (QOL), have become more important to owners. As 
man’s best friend, owners closely monitor their dogs and will go to great lengths to maintain 
health and avoid pain.  
Osteoarthritis (OA), also known as degenerative joint disease or osteoarthrosis, is a 
debilitating, irreversible, lifelong disease that has no cure. In North America, more than 20% of 
dogs greater than the age of 1 suffer from OA (Johnston, 1997). Based on the results of a lifelong 
study conducted on Labrador Retrievers that noted a linear development of OA with age, the 
incidence in aged dogs is much greater (Smith et al., 2006). Therefore, the prevalence of OA is 
even higher in geriatric dogs. More recent data agree, as the Banfield Pet Hospital State of Pet 
Health 2012 Report stated that nearly 1 in 4 geriatric (> 10 years) large (22.7 to 40.9 kg) and 
giant breed dogs (≥ 41 kg) are diagnosed with arthritis.  
 
DEFINING OSTEOARTHRITIS 
 
 Osteoarthritis is a slowly progressive disease of the joint that is affiliated with an 
imbalance of the synthesis and breakdown of articular cartilage and characterized by degradation 
of articular cartilage, osteophyte formation, bone remodeling and subchondral bone thickening, 
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and inflammation of varying degree accompanied by pain and disability (Howell, 1986; 
Johnston, 1997; Sanderson et al., 2009). The specific etiology of OA is unknown, as it is 
considered a complex condition with a multitude of interacting biochemical and biomechanical 
factors. It can be considered an idiopathic disease, or it can be secondary to trauma and cause 
joint deformities. Osteoarthritis may occur from exogenous trauma that puts stress on a joint or 
may occur from normal forces that exacerbate problems on an abnormal joint, such as hip 
dysplasia or osteochondrosis (Johnston, 1997).  
 
JOINT STRUCTURE AND DYSFUNCTION 
Articular Cartilage 
 Hyaline, or articular, cartilage is a smooth, white tissue covering the end of long bones in 
a joint that allows almost frictionless motion and transmits load and shearing force to the 
subchondral bone. Chondrocytes and extracellular matrix are the primary components in 
cartilage. Chondrocytes, the metabolically active cells of cartilage, are responsible for the 
maintenance of the extracellular matrix. Collagen, proteoglycans, and water make up the 
extracellular matrix and work together to distribute force over subchondral bone and allow 
smooth movement of the joint. Structural support of the extracellular matrix in cartilage is 
provided by collagen fibrils and the distribution of proteoglycans among the fibrils. 
Proteoglycans have an affinity for water, which creates a swelling pressure necessary for the 
proper function and compression resistance of the joint. When compression is exerted on a joint, 
water slowly moves through the densely packed, extracellular matrix. Water then will leak onto 
the surface for hydrostatic lubrication. When cartilage fibers are damaged or the connections 
between proteoglycans and collagen fibrils are broken and a compressive force is applied, it can 
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cause damage to the extracellular matrix. This leads to the reduction of the cushioning capacity 
of cartilage and subsequent development of OA (Johnston, 1997).  
 
Subchondral Bone 
 Subchondral bone is a deformable, thin layer of bone in contact with cartilage on one side 
and cancellous bone on the other. It helps support the cartilage by reducing peak load through a 
large contact area distribution (Radin and Paul, 1970). Thickening of the subchondral bone layer 
occurs when the extracellular matrix is damaged and loses its cushioning ability, causing the 
subchondral bone to be exposed to extra force (Johnston, 1997). Recurring trauma to a joint may 
also cause micro-fractures within the subchondral bone, leading to stiffness and decreased 
deformability (Henrotin et al., 2005). 
 
Osteophytes 
 The presence or absence of osteophytes is thought to be a defining point for diagnosing 
OA (Spector et al., 1993). An osteophyte, also called a bone spur, is a bony outgrowth from the 
subchondral bone layer. Osteophytes have been speculated to form because of joint instability.  
In such cases, it is thought that the body attempts to increase the surface area by forming the spur 
to increase joint stability. The exact reason and the method by which this process occurs, 
however, is unknown. Despite the reason for their development, osteophytes tend to cause pain 
during motion because they extend toward the periosteum of bones and alter the normal 
movement of a joint (Johnston, 1997). 
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Joint Cavity 
 The joint cavity, or space between two articulating bones, is comprised of three layers, 
including the synovial membrane (innermost), subsynovial layer (middle), and the fibrous joint 
capsule (outermost). Synoviocytes remove debris from joints and produce cytokines. Synovial 
fluid is composed of electrolytes and other small molecules in similar proportions as plasma. 
Inflammation causes increased permeability of the synovium vasculature, which results in an 
increased protein concentration in synovial fluid and increased exchange of molecules across the 
synovial membrane. Production of cytokines by synoviocytes attracts extra inflammatory cells 
and releases prostaglandins, which cause further damage and continues the degradation of 
cartilage (Pelletier et al., 1985). Also, as articular cartilage is damaged, fragments are broken off 
and initiate an inflammatory response (Ghosh and Smith, 1993). Inflammatory cytokines, such as 
interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), or interleukin-1beta (IL-1β), stimulate 
fibroblasts to increase collagen production, causing joint capsule thickening due to increased 
collagen production (Krasnokutsky et al., 2008). Joint capsule thickening directly relates to 
stiffness, decreased range of motion (ROM) of a joint, and pain all of which are clinical signs of 
OA.  
 
OSTEOARTHRITIS DIAGNOSIS 
Physical Examination 
Diagnosing an animal with OA is most accurate with the use of multiple measurements. 
Along with a medical history, a physical examination can determine if the clinical signs are due 
to OA or a neurologic problem. The physical exam helps to decide which joints are affected by 
OA and establishes a degree of severity, even though it is a bit subjective and may vary from 
veterinarian to veterinarian. An exam also determines if swelling, pain, crepitus, or effusion of 
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the joint are present. Goniometry has been demonstrated to be a reliable method to measure the 
ROM of a joint in dogs (Jaegger et al., 2002). A goniometer is a device that is used to measure 
angles of flexion and extension of a joint. It is likely that a dog experiencing pain will have 
decreased ROM of the respective joint (Jaegger et al., 2002). Unfortunately, because of the 
variability due to breed, age, genetics, joint health, etc., standards for normal ROM of a joint are 
difficult to establish. The study conducted by Jaegger et al. (2002) established normal ROM for 
healthy Labrador Retrievers, but no other breeds. When evaluating the efficacy of a treatment, an 
increase of 5 to 10 degrees of ROM is a sign of improvement in a clinical setting. Over a long-
term situation, the lack of ROM loss may be a positive outcome (personal communication with 
Kim Knap, CVT with 12+ years of experience). 
 
Radiography 
Radiography is a standard method used by veterinarians in diagnosing OA. Although 
joint space narrowing may be a better indicator of disease progression in humans (Spector et al., 
1993), osteophyte formation is the most common feature used to assess OA presence in dogs 
(Innes et al., 2004). Radiographs also show subluxation, effusion, subchondral sclerosis, joint 
space narrowing, and bone remodeling as well as rule out any irregularities that are not related to 
OA (DeLuke et al., 2012; MacPhail, 2000; Rychel, 2010). Veterinarians use a subjective scoring 
system to rank the disease progression based on joint effusion, osteophytosis, subchondral 
sclerosis, intra-articular mineralization, and overall disease severity (Innes et al., 2004). 
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Gait Analysis  
 Gait analysis is the process by which quantitative variables are measured and recorded to 
assess limb functions, gait abnormalities, and to determine the efficacy of treatment interventions 
(Brown et al., 2013; Kim et al., 2011). In most canine studies, force plate platforms embedded 
flush with a walkway are used to measure forces between the walkway and foot that are 
generated when paws contact the floor while walking (McLaughlin, 2001). Peak vertical force 
(PVF) is the maximal force an animal exerts on a force plate per limb. Vertical impulse (VI) is 
the amount of time the animal is exerting pressure on the limb. An increase in both PVF and VI 
compared to baseline would indicate an improvement in joint function and, possibly, reduced 
pain. Gait analysis has been shown to be an effective method of analyzing the gait of an animal 
and determining the effectiveness of a variety of treatments (Gupta et al., 2012; Marshall et al., 
2010; Mlacnik et al., 2006; Rialland et al., 2013). 
 
Biomarkers  
 Given the time, cost, special equipment, and clinical expertise required for current OA 
diagnostic techniques, a need for discovering biomarkers in biological fluids including blood, 
urine, or saliva exists. Reliable biomarkers would not only reduce cost and time involved with 
diagnostics, but early detection of the disease would allow for the use of treatments that slow 
disease progression and extend life span (Mobasheri and Henrotin, 2011; Rorvik and Grondahl, 
1995). The measurement of biomarkers using minimally invasive methods also allows sampling 
over time to monitor disease progression and adjust treatments accordingly (Hegemann et al., 
2002; Lohmander, 1997). Although many candidate biomarkers have been suggested and 
studied, none have been validated to be pre-radiographic biomarkers specific to OA (Mobasheri 
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and Henrotin, 2011). Matrix and bone components, inflammatory cytokines, proteases, and 
protease inhibitors are good OA biomarker candidates (Lohmander, 1997; Patra and Sandell, 
2011; Tseng et al., 2009). Type II collagen epitopes, such as C2C, are considered strong 
biomarkers because they are abundant in cartilage, are relatively specific to articular cartilage, 
and the breakdown of cartilage increases their concentration in synovial fluid and serum 
(Mobasheri and Henrotin, 2011). Matrix metalloproteases (MMPs) are common biomarkers, as 
they are known to break down collagen and proteoglycans in the extracellular matrix (Garner et 
al., 2011; Hegemann et al., 2002). Cartilage oligomeric matrix protein (COMP) interacts with 
collagen and fibrils and is thought to play a role in the structural integrity of the extracellular 
matrix (Tseng et al., 2009). C-reactive protein (CRP) is a positive acute phase protein whose 
concentration increases ≥ 25% in response to pro-inflammatory cytokines (Bennett et al., 2013). 
These, and other biomarkers, have been thought to be good biomarkers for OA in humans and/or 
canines as their concentrations increase with disease progression (Bennett et al., 2013; 
Lohmander, 1997; Mobasheri and Henrotin, 2011). As stated earlier, however, they have been 
used to monitor the severity of disease or response to treatment rather than validated as a pre-
radiographic marker of OA. Because a multitude of biological processes occur in the 
development of OA, a combination of multiple biomarkers may be best to identify early 
progression of the disease (Mobasheri and Henrotin, 2011; Rousseau and Delmas, 2007). 
 
CURRENT TREATMENTS 
Surgery  
The objective of surgery is to relieve pain, re-establish limb function and use, eradicate 
pathologic changes, and prevent the development of, or postpone progression of, pre-existing 
OA (Cook and Payne, 1997; Dahlberg et al., 2005; Eskelinen et al., 2012). Surgery is generally 
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recommended and performed on animals when alternative therapies have been unsuccessful. 
Total joint replacement, most commonly performed on the hip joint, is a biomechanical surgical 
option ideally suited for severely impacted, middle aged patients of medium to large breeds 
(Conzemius and Vandervoort, 2005). Excision arthroplasty is also common in hip joints, but has 
been successful in other joints including the elbow (Conzemius et al., 2003). The procedure 
involves the removal of a piece of the joint that is limiting the function and causing pain, and 
leaving a space that allows the joint to move without impairment (Cook and Payne, 1997). 
Common in unstable joints, athrodesis is the fusion of bones of a joint using plates and screws, 
essentially eliminating the joint itself, and removing the remaining cartilage (Dyce, 1996). This 
procedure can be done in almost any joint, besides the hip joint, and is used to decrease pain and 
ideally improve QOL of the pet.  
 
Pharmacological Agents  
Corticosteroids are steroid hormones made by the adrenal cortex, such as hydrocortisone 
and cortisone. Synthetic mimetics of those hormones are commonly prescribed late in the disease 
course and if the animal is resistant to other treatments. The mechanism is not fully understood, 
but they are likely effective because of their anti-inflammatory properties (Pelletier et al., 1994). 
Limited studies testing the efficacy of corticosteroids have been conducted on dogs, but positive 
results have been reported. One study treated cranial-cruciate ligament sectioned dogs (n = 24) 
with oral prednisone (0.25 mg/kg BW/day) or intra-articular injections of triamcinolone 
hexacetonide (5 mg) at the time of surgery and 4 weeks later, with both treatments resulting in a 
reduction of osteophyte size (P < 0.006 and P < 0.04, respectively) compared to the untreated 
dogs (Pelletier and Martel‐Pelletier, 1989). Another study, conducted by the same researchers, 
  11 
 
tested the effects of intra-articular injections of methylprednisolone acetate (20 mg) at time of 
anterior cruciate ligament sectioning and 4 weeks after surgery, with injections resulting in a 
reduction in incidence (P < 0.004) and size (P < 0.0001) of osteophytes compared with untreated 
dogs (Pelletier et al., 1994). 
The most widely used analgesics in veterinary medicine are nonsteroidal anti-
inflammatory drugs (NSAIDs) (Lascelles et al., 2005) and are a key element in the treatment of 
OA (Aragon et al., 2007; Sanderson et al., 2009). Six NSAIDs have been approved by the US 
Food and Drug Administration for use in dogs: carprofen, meloxicam, tepoxalin, firocoxib, 
deracoxib, and etodolac (Innes et al., 2010). They function by inhibiting the enzyme 
cyclooxygenase (COX) forms 1, 2, or both. COX-1 converts arachidonic acid to prostaglandins 
and thromboxane that regulate normal cell homeostasis, such as vasodilation, nociceptor 
sensitization, renal blood flow maintenance, platelet aggregation, and gastrointestinal (GI) 
mucosal cell turnover (KuKanich et al., 2012). COX-2 synthesizes prostaglandins from 
arachidonic acid that are mediators of pain and inflammation (Cho et al., 2015; Lascelles et al., 
2005; MacPhail, 2000). Aspirin is an over-the-counter NSAID not licensed for dogs, but the 
veterinary prescribed NSAIDs are superior as they cause less GI side effects (Rychel, 2010).  
Owners should be educated on clinical signs associated with the GI-, renal-, or hepatic-
related adverse reactions associated with pharmacological agents (Lascelles et al., 2005; Rychel, 
2010). Dogs with pre-existing kidney, heart, or liver problems, or dehydrated pets, are at highest 
risk for adverse reactions. The most common adverse reactions are GI toxicity resulting in 
ulceration, prolonged bleeding time, renal damage, and liver damage. Clinical signs of NSAID 
toxicity include vomiting, diarrhea, blackened/tarry or bloody feces, and anorexia (Monteiro-
Steagall et al., 2013). A review of 64 NSAID studies reported that adverse reactions were more 
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common in clinical trials (62%) compared to research studies (38%), and the two most common 
signs were vomiting and diarrhea (Monteiro-Steagall et al., 2013). It is hypothesized that 
NSAIDs with COX-2 selectivity, but having a COX-1 sparing effect (termed the coxibs), 
decrease the incidence of adverse effects by preserving the GI mucosa. However, this has not 
been proven in veterinary medicine (Bombardier, 2002; Monteiro-Steagall et al., 2013). Because 
of the known adverse reactions to NSAIDs, other treatment therapies with fewer side effects are 
often sought after. 
 
Weight Loss 
 According to the 2014 National Pet Obesity Awareness Day Survey, approximately 43.8 
million, or 52.7%, of dogs in the United States are overweight or obese (BCS ≥ 4 on a 5-point 
scale) (Association for Pet Obesity, 2014). Because obesity is a risk factor for OA, caloric 
restriction and/or BW loss may be an effective treatment for overweight OA pets (Kealy et al., 
2000). Chronic stress on a joint due to excessive BW has been shown to lead to articular 
cartilage breakdown (Impellizeri et al., 2000; Joshua, 1970). Although the exact mechanism is 
unknown, BW loss is thought to decrease the biomechanical stress placed on joints. A 6-month 
study conducted on OA-stricken, overweight dogs (n = 29; mean age = 8.4 years, BCS ≥ 4 on a 
5-point scale) reported a decrease (P < 0.01) in BW from baseline every 30-day time period for 
up to 6 months after being fed a restricted calorie diet at 60% of the daily metabolizable energy 
requirement of a BW that was set at 15% less than their baseline BW (Mlacnik et al., 2006). That 
study used an objective measure of gait analysis and showed improvements (P < 0.01) in PVF 
and VI on days 60, 120, and 180 compared to baseline in the treatment group fed a restricted 
calorie diet + 2 physical therapy sessions per week giving transcutaneous electrical nerve 
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stimulation. Another study performed in overweight dogs (n = 9; ages 6 to 13 years; BW =         
> 10% ideal BW) suffering from OA were fed 60% less than their normal food intake for up to 
19 weeks and had decreased (P < 0.05) BW (33.4 kg) and BCS (3) compared to baseline (39.0 
and 5, respectively) (Impellizeri et al., 2000). Arguably, the most interesting data for diet 
restriction in dogs suffering from OA comes from a lifelong study conducted on paired Labrador 
Retrievers (n = 48) (Smith et al., 2006). In that study, dogs were either allotted to the control 
group (ad-libitum feeding until 3.25 years, then adjusted to prevent obesity) or the restricted-fed 
group (25% less food than the controls). A difference (P < 0.001) in onset of OA was observed 
between controls (median = 6 years) and restricted-fed (median = 12 years) (Smith et al., 2006). 
Also, at 14 years of age, 83% of dogs in the control treatment were diagnosed with hip OA 
compared to 50% of dogs in the restricted-fed group (Smith et al., 2006). Collectively, these 
results demonstrate that dietary restriction not only decreases BW and BCS and improves gait 
analysis measurements such as PFV and VI, but it also delays the onset of OA in dogs prone to 
developing the disease.  
 
Rehabilitation  
 Osteoarthritis patients are known to have decreased ROM and increased stiffness of 
joints. Rehabilitation therapies, such as stretching, acupuncture, and hydrotherapy, have been 
shown to have positive outcomes on symptoms of OA in dogs (Crook et al., 2007; Levine et al., 
2010; Levine et al., 2004; Millis and Levine, 1997; Nganvongpanit et al., 2014). An at-home 
rehabilitation program for Labrador Retrievers (n = 8; mean age = 7.5 years) suffering from OA 
consisted of stretching the affected joint to full flexion and extension for 10 seconds, 10 
times/day for a total of 21 days (Crook et al., 2007). That rehabilitation strategy resulted in an 
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increase (P < 0.0005) in the ROM of the affected joint for all dogs compared to baseline 
measured by goniometry, with a mean of 14.6° for joint flexion (Crook et al., 2007). Successful 
treatment using rehabilitation therapies could reduce the need for pharmaceutical products as a 
treatment of OA. 
 Acupuncture is an alternative method for pain management of OA. The exact 
mechanisms by which acupuncture may function are not completely understood, but is believed 
to be related to the release of endogenous endorphins that change the nociceptive pain, pain 
arising from the stimulation of nerve cells, as well as the decrease of perceived pain and increase 
blood circulation and muscle spasm relief (Mittleman and Gaynor, 2000). A study was 
conducted on 61 OA dogs (117 joints), with acupuncture treatment using 28 gauge, 5 cm long 
needles for 15 minutes once a week for at least 3 weeks or until a satisfactory result was 
achieved. Results were scored on a 5-point scale, with 1 being no improvement and 5 being 
perfect by veterinarians and owners (Janssens, 1986). The results of that study noted that the use 
of the acupuncture treatment led to scores of 4 or 5 in 62% of the dogs, but the authors did not 
note whether these scores were from the owner or veterinarian. That study included no placebo 
group and the treatment was not blinded. Acupuncture as a sole treatment for OA is not effective 
enough to reduce lameness, but in conjunction with other treatments, it may help to improve 
QOL with almost immediate improvements in mobility, demeanor, and levels of pain (Kapatkin 
et al., 2006; Rychel, 2010).  
 Aquatic therapy is especially good for OA dogs, as buoyancy decreases the weight- 
bearing force, which allows further flexibility of an affected joint (Levine et al., 2004). A study 
conducted on healthy dogs (n = 10; mean age = 5.7 years; mean BW = 25.4 kg) tested the 
vertical ground reaction force (vGRF), the force with the largest magnitude that the ground 
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imparts on the body in the vertical direction, at 3 water levels (tarsal, stifle, and hip joints) and 
demonstrated a reduction (P < 0.001) of vGRF of 9, 15, and 62%, respectively (Levine et al., 
2010). A hydrotherapy study conducted by Nganvongpanit et al. (2014) assigned dogs to three 
treatments: OA-SW (OA + swimming; n = 22), H-SW (healthy + swimming; n = 18), and H-
NSW (healthy + no swimming; n = 15). Dogs in the swimming treatment groups were allowed 
three 20-minute swim times in an outdoor pool twice a week for a period of 8 weeks. Lameness, 
joint mobility, pain on palpation, weight-bearing, and overall scores of the OA-SW group were 
decreased (P < 0.05) on week 8 (2.48; 1.48; 1.48; 1.48; 1.19, respectively) compared to baseline 
(3.00; 1.76; 2.00; 2.05; 1.62, respectively) using a subjective test conducted by two veterinarians 
30-minutes apart (Nganvongpanit et al., 2014). Flexion and extension of both hip joints also 
were improved (P < 0.05) at week 8 compared to baseline for the OA-SW group (Nganvongpanit 
et al., 2014). Hydrotherapy, in the form of underwater treadmill or swimming pools, is an 
effective form of therapy shown to improve ROM and decrease clinical signs of OA by both 
subjective and objective measures.  
 
COMMON NUTRACEUTICALS 
 
Glucosamine and Chondroitin 
 Because glucosamine and chondroitin are components of proteoglycans in articular 
cartilage, they are logical therapeutic agents to treat OA (Bottegoni et al., 2014; Huskisson, 
2008). Glucosamine is made from glucose and is a component of glycosaminoglycan chains, 
which make up proteoglycans. Because articular damage is associated with OA, it is thought that 
glucosamine is a substrate that may help repair cartilage through proteoglycan synthesis 
(Šimáneka et al., 2005). Chondroitin sulfate makes up the majority of glycosaminoglycans, 
  16 
 
therefore it is important for the structure of cartilage. It is also known to reduce the concentration 
of pro-inflammatory cytokines (Bottegoni et al., 2014). The use of CS and glucosamine together 
have been shown to work additively to help decrease the advancement of OA by favoring matrix 
synthesis and repairing articular cartilage (Clegg et al., 2006; Johnson et al., 2001). 
 It is important to note how bioavailable GH and CS are after oral administration of 
supplements. A study conducted by Adebowale et al. (2002) used healthy beagle dogs (n = 8) to 
determine the bioavailability of GH and CS after a single dose in a crossover study with the 
following treatments: (A) IV solution of 500 mg GH and 400 mg low molecular weight CS 
(LMWCS), (B) 1500 mg GH and 1200 mg LMWCS, and (C) 2000 mg GH and 1600 mg 
LMWCS. They also conducted a study to test the bioavailability after multiple doses of 1500 mg 
GH and 1200 mg LMWCS for the first 7 days, before increasing the dose to 3000 mg GH and 
2400 mg LMWCS for days 8 to 14 (Adebowale et al., 2002). The results indicated that GH had a 
mean bioavailability of 12.1 to 12.7% and CS as total disaccharides was 4.8 to 5.0% bioavailable 
after a single dose (Adebowale et al., 2002).    
 These two compounds have been shown to reduce the symptoms commonly associated 
with OA. A double-blind, positive-controlled study reported positive effects of GH/CS in dogs (n 
= 35) suffering from OA by testing a supplement containing the following active ingredients: GH 
at 475 mg/g, CS at 350 mg/g, N-acetyl-D-glucosamine at 50 mg/g, ascorbic acid at 50 mg/g, and 
zinc sulfate at 30 mg/g (McCarthy et al., 2007). For the first 70 days, the supplement was dosed 
at 1 g active ingredient twice daily for 5 to 19.9 kg dogs, 1.5 g twice daily for 20 to 40 kg dogs, 
and 2 g active ingredient twice daily for dogs weighing > 40 kg (McCarthy et al., 2007). The 
dose then was reduced by 1/3 for the next 28 days (McCarthy et al., 2007). In that study, 
improvements (P < 0.001) in overall score of condition, pain on palpation, and weight-bearing 
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from baseline scores were observed. Another group of OA dogs (n = 7 to 10) showed a reduction 
(P < 0.05) in observational pain overall (51%), after limb manipulation (48%), and after physical 
exertion (43%) after 150 days of supplementation of 2000 mg GH and 1600 mg CS per day (P < 
0.05) in a double-blind, placebo-controlled study (Gupta et al., 2012). Although some studies 
have shown improved pain assessment and joint mobility, other studies that have not shown 
significant effects of GH and/or CS on symptoms of OA (D'Altilio et al., 2007; Dobenecker et 
al., 2002; Moreau et al., 2003). 
 
Fish Oil 
Fish oil is known to contain eicosapentaenoic acid (EPA) and docosahexaenoic acid 
(DHA), which are long-chain omega-3 fatty acids. These fatty acids are associated with 
inhibiting synthesis and decreasing serum concentrations of pro-inflammatory cytokines, such as 
TNF-α, IL-1β, and IL-6 (Curtis et al., 2000; Hall et al., 2006; Hielm-Bjorkman et al., 2012). 
Omega-3 fatty acids also have been shown to decrease the activity of MMPs, a factor in cartilage 
degradation, and increase tissue inhibitor MMP-2 (Hansen et al., 2008) as well as decrease 
arachidonic acid concentrations (Calder and Zurier, 2001). A study conducted on mixed-breed 
OA-stricken dogs (n = 71) tested the supplementation of fish oil to a commercial diet at an 
average of 110.25 mg/kg BW of EPA and DHA for 16 weeks. No differences in PVF, VI, and 
use of NSAIDs were reported between treatment groups (Hielm-Bjorkman et al., 2012). There 
was an increase (P = 0.021) of PVF for the fish oil group from baseline to the end of the study 
and a trend towards improvement for VI (P = 0.092) (Hielm-Bjorkman et al., 2012). A 6-month, 
multicenter study with dogs suffering from OA (n = 127) tested a food supplemented with 3.5% 
fish oil-based omega-3 fatty acids compared to the control diet (Roush et al., 2010a). In that 
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study, owners subjectively observed improvements in their dog’s ability to rise from a resting 
position (P = 0.033) and reluctance to play (P = 0.011) between weeks 0 and 6 for the test food 
compared to the control. Between weeks 6 to 12 and weeks 12 to 24, dogs fed the test diet had 
improvements (P = 0.024 and P = 0.003, respectively) in their ability to walk compared to the 
control (Roush et al., 2010a). The same study by Roush et al. (2010a) resulted in increased (P < 
0.001) serum concentrations of omega-3 fatty acids and decreased (P < 0.001) serum 
concentrations of arachidonic acid in the test group vs. the controls, indicating that the fish oil-
based omega-3 fatty acids were bioavailable. Another multicenter study conducted on OA dogs 
(n = 109) standardized the dose of carprofen, an NSAID, to 4.4 mg/kg BW/day and assigned 
dogs to a control or test diet feeding the same diets as in the Roush et al. (2010a) study for 12 
weeks (Fritsch et al., 2010). In that study, a more rapid decrease (P = 0.025) in carprofen dosage 
was reported for dogs fed the test diet compared to those fed the control (Fritsch et al., 2010). 
Roush et al. (2010b) conducted a similar study in OA dogs (n = 38) over 90 days using the same 
diets as described in Roush et al. (2010a). Although they did not observe differences between the 
test diet and the control for PVF, they observed a mean PFV change (+5.6%; P = 0.01) in the test 
group from day 0 to day 90, indicating that fish oil may improve weight-bearing ability of dogs 
suffering from OA (Roush et al., 2010b).  
 
Green-Lipped Mussel 
The New Zealand green-lipped mussel (GLM), Perna canaliculus, is a newer 
nutraceutical that contains many nutrients, including vitamins, minerals, omega-3 fatty acids, and 
glycosaminoglycans patented by Mars Inc. (Bui et al., 2003; Hielm-Bjorkman et al., 2009). 
Green-lipped mussel is known to have anti-inflammatory properties with active ingredients 
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including the presence of eicosatetraenoiec acid and a blend of other unique fatty acids (Bierer 
and Bui, 2002; Bui et al., 2003; Hielm-Bjorkman et al., 2009; Servet et al., 2006). It can be 
incorporated into food through a freeze-dried powder or as an oil extract (Pollard et al., 2006). 
One group of researchers conducted a series of 3 clinical studies on dogs (age range: 4 to 13 
years; n = 31 to 33/study) with signs of arthritis and evaluated the effects of GLM as a powdered 
supplement fed on top of a control diet (< 25 kg BW = 450 mg GLM/day; 25 to 34 kg BW = 750 
mg GLM/day; > 34 kg BW = 1000 mg GLM/day), or incorporated into a treat or dry main meal 
diet for a period of 6 weeks (Bierer and Bui, 2002). A veterinarian scored each dog for lameness 
when walking, trotting, and climbing stairs, resulting in a “visual score”. Individual joints were 
scored for the degree of pain, swelling, crepitus, and mobility reduction and then summed to 
provide a “manipulation score”. Those two scores then were averaged to give a “total arthritic 
score” (TAS). For all three studies, total arthritic score, joint pain, and joint swelling were 
reduced (P < 0.05) in the GLM treated groups compared to the control (Bierer and Bui, 2002). A 
multicenter study was conducted over 50 days on OA-stricken dogs (n = 85) evaluating the 
effects of GLM incorporated into an extruded diet at a dose of 0.3% (Servet et al., 2006). 
Veterinarians subjectively scored the dogs using the same variables as in the previous study 
(Bierer and Bui, 2002) for visual score, manipulation score, and TAS. All three scores were 
reduced (P < 0.05) by 36, 33, and 34%, respectively for the GLM group on day 50 compared to 
baseline (Servet et al., 2006). A study conducted by Pollard et al. (2006) tested a GLM 
supplement with 125 mg/tablet in dogs with OA over 56 days (n = 81; mean age 8.5 years). In 
that study, dogs weighing 5 to 15 kg received 3 tablets/day, 16 to 20 kg dogs received 5 
tablets/day, 21 to 25 kg dogs received 6 tablets/day, 26 to 45 kg dogs received 8 tablets/day, and 
46 to 65 kg dogs received 9 tablets/day. The study showed that 67% of the dogs in the GLM 
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group had improved clinical assessment scores compared to 41% in the placebo (P = 0.018) after 
56 days (Pollard et al., 2006). Finally, a study was conducted on dogs suffering from OA (n = 
23), with dogs fed a control diet for 30 days before being switched to a test diet enriched with 
GLM for 60 days (Rialland et al., 2013). That study tested gait analysis, with GLM treatment 
resulting in increased (P = 0.0004) PVF at the end of the study compared to baseline (Rialland et 
al., 2013). Because GLM is heat-sensitive, special processing conditions using cold extraction 
should be accounted for (Bierer and Bui, 2002; Servet et al., 2006).   
 
Calcium Fructoborate 
 Calcium fructoborate, patented as FruiteX-B® by VDF FutureCeuticals, Inc., is a 
manufactured mimetic of a naturally occurring compound found in plants, including various 
herbs, fruits, and vegetables (Miljkovic, 1999; Miljkovic et al., 2009). Composed of calcium and 
two fructose molecules bound to boron, CFB is water-soluble and approximately 5% calcium, 
92.3% fructose, and 2.7% boron with the linear formula Ca[(C6H10O6)2B]24H2O (Scorei and 
Rotaru, 2011). Calcium fructoborate has been shown to have no adverse effects and multiple 
beneficial effects in humans, including antioxidant and anti-inflammatory properties, anti-tumor 
effects, and ability to reduce pain and improve function of arthritic joints.  
In vitro studies, using human keratinocytes, neutrophils, and macrophages, have been 
conducted to evaluate the antioxidant and anti-inflammatory properties of CFB. It is believed 
that CFB is a scavenger of superoxide radicals. A study was conducted to test pre-incubation 
concentrations (0, 45, 90, and 450 nmol) of CFB on human keratinocytes exposed to 100 µmol 
H2O2 for an hour to simulate oxidative stress (Scorei et al., 2005). In that study, there was a 
reduced concentration of reactive oxygen species (ROS) after pre-incubation with CFB, but it 
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was not directly proportional to the dose applied because the maximum antioxidant activity was 
observed at 90 nmol CFB (Scorei et al., 2005). A second study, whereby human 
polymorphonuclear neutrophils were subjected to 22,500 µM of CFB for 24 hours, observed a 
92.9% decrease in ROS levels (Scorei et al., 2007). Another study measured the production of 
inflammatory markers by lipopolysaccharide (LPS)-stimulated murine macrophage RAW 264.7 
cells exposed to 0.2, 0.45, or 1 mM CFB for 24 hours (Scorei et al., 2010). In the same study by 
Scorei et al. (2010), CFB decreased (P < 0.01) IL-1β concentrations by 27% and IL-6 by 90% 
compared to control cells exposed to LPS without CFB treatment. 
Because in vitro data were promising, in vivo human studies evaluating CFB dose and 
effectiveness on modulating inflammatory biomarkers were conducted. In a 15-day study 
conducted in humans (n = 15; ages 59 to 68 years) suffering from primary OA, participants were 
supplemented with 28.5 mg CFB twice daily (Scorei et al., 2011). In that study, whole blood 
erythrocyte sedimentation rate, plasma fibrinogen, and serum CRP concentrations were 
decreased (P < 0.05) 10.25, 13.73, and 60.25%, respectively, with CFB treatment compared to 
baseline. Serum CRP concentrations were shown to be reduced (P = 0.0102) by 37% compared 
to baseline in a study of adult humans (n = 9 to 10; ages 44 to 65 years) afflicted with knee OA 
after supplementation of 216 mg/day CFB for 14 days (Reyes-Izquierdo et al., 2012). More 
research testing CFB at a rate of 112 mg/day for 30 days in healthy human adults (n = 26; ages 
40 to 60) resulted in a 31.3% reduction (P < 0.05) of serum CRP compared to baseline 
(Rogoveanu et al., 2015). In addition to CRP, the blood markers, low-density lipoprotein, 
homocysteine, triglycerides, IL-1β, and monocyte chemoattractant protein-1 were reduced (P < 
0.05) (9.8, 5.5, 9.1, 29.2, and 31%, respectively) compared to baseline, after 30 days of CFB 
supplementation at a dose of 112 mg/day (Rogoveanu et al., 2015).  
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Relieving the pain and discomfort associated with OA is a high priority for researchers 
and pet owners. The Western Ontario and McMaster Universities Arthritis Index (WOMAC) 
(Bellamy, 1988) and McGill Pain Questionnaire (MPQ) (Melzack, 1975; Melzack, 2005) are 
questionnaires commonly used to assess physical function and pain of human patients suffering 
from OA. These surveys may be used to determine the effectiveness of an intervention with the 
goal of observing decreased scores, representing less pain and physical limitations. After 14 days 
supplementation with CFB at a dose of 220 mg/day, human adults with self-reported knee 
discomfort (n = 60; mean age = 49.2 years) showed a 13.73-point reduction in WOMAC score 
and an 8.9-point reduction in MPQ score (P < 0.0001) (Pietrzkowski et al., 2014). The study 
conducted by Reyes-Izquierdo et al. (2012) resulted in decreased (P < 0.01) WOMAC (-22.2 
points) and MPQ (-14%) scores after 14 days supplementation with CFB at 216 mg/day. An OA 
clinical trial tested different doses of CFB in patients (n = 20) suffering from mild to medium 
OA cases (6 mg CFB/day) and severe OA cases (12 mg CFB/day) (Miljkovic, unpublished data, 
2002). Some interesting results were that within eight weeks, CFB was believed to be an 
effective painkiller in both mildly- and severely- affected patients by allowing 67 and 75% of the 
patients, respectively, to eliminate or reduce the amount of painkillers needed (P < 0.05) 
(Miljkovic, unpublished data, 2002). Table 2.1 displays the main results of five studies 
conducted on humans testing CFB. Calcium fructoborate shows promise of being effective at 
decreasing pain and improving the symptoms associated with OA, but this supplement has not 
been tested in dogs to see if it would have the same effects.
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TABLE 
 
Table 2.1. Human studies evaluating the effects of CFB on blood markers and pain symptoms associated with OA* 
Reference 
Age 
(yr) n Treatments 
CFB doses 
(mg/day) 
Length of 
treatment Major outcomes of CFB supplementation (P < 0.05) 
Miljkovic, unpublished data, 
2012 N/A 
20 
total 
Mild and medium 
forms 6 8 weeks 
CFB for mild to medium forms of OA eliminated the need for other painkillers in 67% 
of the patients 
   Severe forms 12  
CFB for severe forms of OA eliminated or decreased the amount of painkillers in 75% 
of the patients 
Scorei et al., 2011 
59-
68 15 Placebo 0 (fructose) 15 days CFB 1 decreased whole blood ESR concentrations compared to baseline by -10.25% 
  
15 CFB-1 57 
 
CFB 1 decreased plasma FBR concentrations compared to baseline by -13.73%  
  
15 CFB-2 113 
 
CFB 1 decreased serum CRP concentrations compared to baseline by -60.25% 
  
15 CFB-3 226 
  
Reyes-Izquierdo et al., 2012 
44-
65 10 Placebo 0 (fructose) 14 days Day 7 WOMAC scores decreased by 14.1 points compared to baseline 
  
9 CFB 216 
 
Day 14 WOMAC scores decreased by 22.2 points compared to baseline  
      
Day 7 MPQ scores in 8/10 subjects reduced 13% compared to baseline 
      
Day 14 MPQ scores in 8/10 subjects reduced 14% compared to baseline 
      
Day 7 serum CRP levels in 7/10 subjects reduced 27% compared to baseline  
      
Day 14 serum CRP levels in 7/10 subjects reduced 37% compared to baseline  
Pietrzowski et al., 2014 
35-
65 30 Placebo 0 (fructose) 14 days Day 14 WOMAC scores decreased by 13.73 points compared to baseline  
  
30 CFB 220 
 
Day 7 MPQ scores decreased by 5.8 points compared to baseline  
      
Day 14 MPQ scores decreased by 8.9 points compared to baseline  
Rogoveanu et al., 2015 
40-
60 26 Placebo 0 (fructose)  30 days CFB-1 decreased serum CRP concentrations compared to baseline by -31.3% 
  
26 CFB-1 112 
 
CFB-1 and CFB-2 decreased serum LDL concentrations compared to baseline by -9.8 
and -9.4%, respectively 
  
26 CFB-2 56 
 
CFB-1 decreased serum homocysteine concentrations compared to baseline by -5.5% 
      
CFB-1 and CFB-2 decreased serum triglyceride concentrations compared to baseline by 
-9.1 and -8.8%, respectively 
      
CFB-1 decreased serum IL-1β concentrations compared to baseline by -29.2% 
      
CFB-1 and CFB-2 decreased serum MCP-1 concentrations compared to baseline by -31 
and -26%, respectively 
*OA: osteoarthritis; CFB: calcium fructoborate; N/A: not available; ESR: erythrocyte sedimentation rate; FBR: fibrinogen; CRP: c-reactive protein; WOMAC: Western Ontario and 
McMaster Universities Arthritis Index; MPQ: McGill Pain Questionnaire; LDL: low-density lipoprotein; IL-1β: interleukin-1β; MCP-1: monocyte chemoattractant protein-1. 
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Chapter 3 
 
Effects of Dietary Calcium Fructoborate Supplementation on Joint Comfort and 
Flexibility and Serum Inflammatory Markers in Dogs with Osteoarthritis 
ABSTRACT 
 
Symptoms of osteoarthritis (OA) afflict approximately 20% of adult dogs in North 
America. Clinical signs consistent with OA include decreased range of motion of a joint, reduced 
physical activity, difficulty climbing stairs or onto furniture, and a reduced ability to rise from a 
lying position. A safe and effective nutraceutical supplement may benefit dogs suffering from 
OA. Calcium fructoborate (CFB), a mimetic of a naturally occurring molecule, has previously 
been reported to be safe and effective in humans with joint problems. The objective of this 
randomized, double-blinded, placebo-controlled study was to evaluate the short-term effects of 
CFB alone, or in combination with a blend of glucosamine hydrochloride (GH) and chondroitin 
sulfate (CS), on gait analysis, goniometry, serum inflammatory markers, and owner perception of 
pain in client-owned dogs. Sixty-four dogs with joint discomfort were recruited and 59 dogs 
(mean age = 8.42 ± 0.37 yr.; mean BW = 31.11 ± 1.28 kg) completed the study. All procedures 
were approved by the University of Illinois Institutional Animal Care and Use Committee, and 
pet owners signed an informed consent prior to study initiation. Dogs were randomly assigned to 
one of four treatments: placebo (60 mg fructose; n = 15), low dose (69 mg CFB; n = 14), high 
dose (127 mg CFB; n = 14), or combination (69 mg CFB, 500 mg GH and 200 mg CS; n = 16). 
Treatments were provided once daily as dietary supplements. Small dogs weighing up to 22.9 kg 
received 1 capsule/day, while large dogs weighing 23 to 50 kg received 2 capsules/day for 28 
days. A physical examination, radiographs, goniometry measurements, gait analysis, blood 
sample collection, and the canine brief pain inventory (CBPI) questionnaire were performed and 
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administered on days 0 and 28. As expected, a majority (69%) of the dogs were overweight or 
obese, with a body condition score (BCS) > 6 on a 9-point scale. Dogs fed the low dose (-2.93) 
and high dose (-2.21) of CFB were shown to improve (P < 0.05) in their ability to rise from a 
lying position from day 0 to day 28 compared to dogs fed the placebo (0.00), but no difference 
was observed for dogs fed the combination treatment. Dogs assigned the low dose of CFB also 
tended to have an improved pain severity score (PSS; -1.46; P = 0.08) and pain at its worst score 
(-2.14; P = 0.06) from day 0 to day 28 compared to dogs fed the placebo (0.05 and 0.00, 
respectively). Dogs fed the high dose of CFB had a greater increase (P = 0.05) in serum 
concentration of soluble receptor for advanced glycation end products (sRAGE) from day 0 to 
day 28 (7.88 ng/mL) compared to dogs fed the placebo (0.83 ng/mL). All blood metabolites were 
within reference range except total alkaline phosphatase and corticosteroid-induced alkaline 
phosphatase, which started and ended at concentrations greater than the upper reference range. 
Dogs assigned the high dose of CFB tended to have a greater reduction (P = 0.07) in serum 
chloride from day 0 to day 28 (-1.64 mmol/L) compared to dogs fed the low dose of CFB (0.08 
mmol/L). Given the low number of small dogs recruited and the increased variability noted as a 
result of their inclusion, a sub-analysis of large dogs only was performed. Large dogs fed the low 
dose were shown to have decreased (P < 0.05) scores for PSS (-1.77) and pain at its worst (-2.45) 
from day 0 to day 28 compared to the placebo group (0.19 and 0.42, respectively). Large dogs 
assigned the low dose of CFB tended to have improved scores for pain at its least (-1.27; P = 
0.08) and pain on average (-1.82; P = 0.07) from day 0 to day 28 compared to dogs fed the 
placebo (0.25 and -0.08, respectively), but no difference was observed for dogs fed the high dose 
or combination groups. Large dogs fed the low dose also were shown to improve (P < 0.05) in 
their ability to rise from a lying position (-3.09) compared to the placebo treatment (0.25) from 
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day 0 to day 28. Overall, supplementation of CFB alone was well-tolerated and appeared to have 
potential for joint discomfort mitigation in canines. 
 
INTRODUCTION 
 
Classifying pets as members of the family is a growing trend in the United States. In 
2011, 63.2% of owners viewed their pets as members of the family (American Veterinary 
Medical Association, 2012). With that trend, a pet’s health, lifespan, and quality of life (QOL) 
have become increasingly important to owners. The American Pet Products Association reported 
that 65% of the households in the United States own a pet, including a population of over 77 
million dogs (American Pet Products Association, 2015). As man’s best friend, owners closely 
monitor their dogs and will go to great lengths to maintain health and avoid pain.  
Osteoarthritis, also known as degenerative joint disease or osteoarthrosis, is a debilitating, 
irreversible, lifelong disease that has no cure. In North America, over 20% of dogs over the age 
of 1 suffer from OA (Johnston, 1997). Based on the results of a lifelong study conducted on 
Labrador Retrievers that noted a linear development of OA with age, the incidence in aged dogs 
is much greater (Smith et al., 2006). Therefore, the prevalence of OA is even higher in geriatric 
dogs. Osteoarthritis affects mainly the hips, elbows, and stifles of dogs, but also can cause 
problems in vertebral, carpal, and tarsal joints. Common clinical signs include pain, tenderness, 
decreased range of motion (ROM), swelling, stiffness, muscle atrophy, crepitus, and effusion. 
Due to the pain and other symptoms, an affected dog’s behavior may change and lead to 
aggression, decreased activity, limping, problems rising from a lying position, and difficulty 
climbing stairs or onto furniture. Age is the main risk factor of OA, but other predisposing 
factors include genetics, size of the breed, obesity, joint deformity, trauma and fractures, surgery, 
and elbow or hip dysplasia (MacPhail, 2000; Rychel, 2010; Sandell, 2012).  
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Although there is no cure for OA, modalities exist such that the disease may be managed, 
resulting in slowed progression and decreased pain and signs associated with the disease. 
Treatment of OA aims to improve QOL of the animal by relieving pain, decreasing 
inflammation, increasing activity level, and increasing ROM of the joint (MacPhail, 2000). 
Nutraceuticals, food or dietary supplements that offer a health or medical benefit have become 
popular treatments for OA. Some treatments already exist, but novel nutraceuticals are being 
sought by the industry. Calcium fructoborate is a naturally-occurring plant-mineral complex 
found in certain fruits, nuts, and legumes. It is commercially manufactured from a proprietary 
reaction of fructose, calcium, and boric acid that produces a nature-identical molecule composed 
of calcium bound to mono- and di-fructoborate complexes. Calcium fructoborate has been shown 
to positively affect humans suffering from symptoms of OA in several clinical studies, but has 
yet to be tested in dogs. Therefore, the objective of this study was to evaluate the short-term 
effects of CFB alone, or in combination with a blend of GH and CS, on serum inflammatory 
markers, goniometry, gait analysis, and owner perception of pain in client-owned dogs. It was 
hypothesized that the CFB treatment would improve joint mobility, decrease pain, and decrease 
inflammatory markers. 
 
MATERIALS AND METHODS 
 
Animals and Study Design 
Sixty-four adult dogs of various breeds were recruited and fifty-nine dogs (mean age = 
8.42 ± 0.37 yr; mean BW = 31.11 ± 1.28 kg; mean BCS = 6.41 ± 0.15) completed a double-
blinded, placebo-controlled study in a completely randomized design. Dogs were selected based 
on clinical signs, history, and orthopedic exams consistent with osteoarthritis. The University of 
Illinois Animal Care and Use Committee approved all procedures, and pet owners signed an 
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informed consent form prior to study initiation. The current exercise regimen and diet 
information were collected for each dog (Figures 3.1 to 3.3). A 14-day washout period prior to 
enrollment was required for animals being treated with interfering medications including 
corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), and nutraceuticals. Prior to 
initiation, dogs underwent physical, neurological, and orthopedic examinations conducted by Dr. 
Tisha Harper, DVM, board-certified small animal surgeon, followed by a radiograph 
examination performed by Dr. Stephen Joslyn, BVMS, board-certified radiologist, to determine 
the most affected joint and clinically infer the dogs with OA at the University of Illinois 
Veterinary Teaching Hospital. For the dogs that completed the study, 8.5, 52.5, and 39.0% were 
diagnosed with elbow, stifle, and hip OA, respectively. The study was 28 days in length, which 
was twice the length of CFB studies with positive outcomes in humans, and dogs and owners 
visited the clinic on days 0 and 28.  
 
Exclusion Criteria 
 Dogs not able to remain off interfering medications during the washout period and during 
the 28-day study period were excluded from the study. Also excluded from the study were dogs 
having evidence of a neurological disease that could affect the outcome measures, malignant 
neoplasia, or acute instability of the joint.  
 
Treatments 
 Treatments were provided as dietary supplements distributed in capsules of the same size, 
color, and shape provided by FutureCeuticals, Inc. (Momence, IL). Each capsule contained the 
following active ingredients: placebo = none (60 mg fructose); low dose = 69 mg CFB; high 
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dose = 127 mg CFB; and combination = 69 mg CFB, 500 mg GH, and 200 mg CS (769 mg 
total). Dosages were based on allometric conversions from dosages tested in humans. Dogs were 
assigned to treatments through a continuous enrollment over a period of six months and stratified 
based on BW. A balanced but random allotment was performed so that an equal number of dogs 
within each BW range were placed on all treatments. Small dogs (BW range: 10 to 22.9 kg) 
received one capsule/day while large dogs (BW range: 23 to 50 kg) received two capsules/day of 
their respective treatments throughout the study. Ingestion of the supplements was facilitated by 
use of Pill Pockets® (The Nutro Company, Franklin, TN). 
 
Goniometry  
 Angles of flexion and extension were analyzed to determine the range of motion of the 
most affected joint (hip, elbow, or stifle) of each dog on days 0 and 28 as described previously 
(Jaegger et al., 2002). To summarize, the center of the goniometer was positioned over the 
isometric center of the joint with the long axes placed over the proximal and distal long bones. 
Limbs were flexed or extended fully and measurements then were recorded.  
 
Gait Analysis 
 Gait analysis was measured on days 0 and 28 by use of a Tekscan walkway (7100 QL 
Virtual Sensor 4 Mat System, Tekscan, Boston, MA). Dogs walked at a consistent pace of ± 1.50 
m/s and acceleration of ± 0.50 m/s2. A valid walk consisted of the dogs walking within the 
parameter of the mat and without sidestepping or shaking its head. Multiple walks were recorded 
per dog per visit to ensure that 5 footfalls could be averaged per visit to use for analysis. Vertical 
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impulse (VI) and peak vertical force (PVF), expressed as a percentage of BW, of the most 
affected joint were used for analysis (McLaughlin, 2001).  
 
Radiographic Assessment 
Radiographic examination was performed on the most affected limb on days 0 and 28. 
For proper positioning of radiographs, dogs were sedated intramuscularly or intravenously with 
dexmedetomidine hydrochloride (3.3 to 4.4 μg/kg BW) and butorphanol (0.2 mg/kg BW). Dogs 
were fasted overnight prior to sedation. Different protocols were used depending on the most 
affected joint: hip: a lateral and an extended ventrodorsal pelvis projection as per the British 
Veterinary Association/Kennel Club hip scoring guidelines (Dennis, 2012); elbow: one 
craniocaudal and one medio-lateral projection taken of the elbow with the radio-humeral angle 
positioned at 45° following the international elbow working group protocol (http://www.vet-
iewg.org/joomla/index.php/archive/23-2001-international-elbow-protocol-vancouver); or stifle: a 
caudo-cranial and medio-lateral projection of the stifle assessed according to Innes et al. (2004). 
 
Serum Chemistry and Inflammatory Marker Analyses 
 On days 0 and 28, up to 20 mL of blood was collected via radial or jugular venipuncture, 
after fasting overnight, while the animal was still under sedation for radiographic assessment. 
Blood was collected into BD Vacutainer® SST™ (Becton, Dickinson and Company, Franklin 
Lakes, NJ) and Monoject™ tubes (Covidien, Mansfield, MA). Blood was allowed to clot at room 
temperature before it was centrifuged at 1210 g for 15 minutes at 4°C. Serum from the 
Monoject™ tube was used for serum chemistry analyses using a Hitachi 911 clinical chemistry 
analyzer (Roche Diagnostics, Indianapolis, IN). The remaining serum was pipetted into 
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cryogenic vials and stored at -80°C until it was shipped to Applied BioClinical, Inc. (Irvine, CA) 
on dry ice for the analysis of inflammatory and OA markers. Canine-specific, commercialized, 
enzyme-linked immunosorbent assay kits were used to measure cartilage oligomeric matrix 
protein (COMP; MBS733921; MyBioSource, San Diego, CA), C-reactive protein (CRP; 
ab157698; Abcam, Cambridge, MA), matrix metalloproteinase 3 (MMP3; SEA101Ca; Cloud-
Clone Corp., Houston, TX), follistatin-like protein-1 (FSTL; ABIN1053764; Antibodies-online, 
Atlanta, GA), c-terminal cross-linked telopeptide type II collagen (CTX-II; MBS744225; 
MyBioSource, San Diego, CA), hyaluronan (DHYAL0; R&D Systems, Minneapolis, MN), 
Col2-3/4C (long mono) (C2C; MBS755913; MyBioSource, San Diego, CA), soluble receptor for 
advanced glycation end products (sRAGE; CS0290; NeoBioLab, Cambridge, MA), chitinase 3-
like protein 1 (CHI3L; E08C1675; American Research Products, Inc., Waltham, MA), and 
interleukin 6 (IL-6; CA600; R&D Systems, Minneapolis, MN).  
 
Canine Brief Pain Inventory 
 The same owner of each dog completed the canine brief pain inventory (CBPI) survey on 
days 0 and 28. The CBPI is a validated survey for OA and bone cancer developed by researchers 
at the University of Pennsylvania (Brown et al., 2008). The survey consists of a series of ten 
questions rating the dog’s pain and how it interferes with the animal’s normal daily routine on a 
numerical scale from 0 to 10, with “0” representing no pain/interference and “10” representing 
extreme pain/interference. Four questions pertaining to the dog’s pain in the previous 7 days 
were averaged to create the PSS and six questions concerning how much the dog’s pain 
interferes with their normal activity were averaged to create the pain interference score (PIS). 
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One additional qualitative question asked the owner to rate the QOL of their animal using 
descriptors from poor to excellent. 
 
Statistical Analysis 
 All data were analyzed using the Mixed Models procedure of SAS® (version 9.4; SAS 
Institute, Inc., Cary, NC). Because day 0 data were highly variable, the differences between day 
28 and day 0 were evaluated statistically. Normality was evaluated using Proc Univariate. For 
non-normally distributed data, the observed values were reported after the data had been 
transformed using the log function prior to statistical analysis. To control for experiment-wise 
error, means were separated using a Fisher-protected least significant difference with Tukey’s 
adjustment. Probabilities of P ≤ 0.05 were accepted as significant, and P ≤ 0.10 were considered 
trends. Because the majority of the dogs were large and there was a great deal of variability in 
the data, a sub-analysis of data from dogs over 23 kg also was conducted. 
 
RESULTS 
 
Analysis of All Dogs 
 The results for the CBPI data from all dogs are summarized in Table 3.1. Dogs fed the 
low dose (-2.93) and high dose (-2.21) of CFB were shown to improve (P < 0.05) in their ability 
to rise from a lying position from day 0 to day 28 compared to dogs fed the placebo (0.00), but 
no difference was observed for dogs fed the combination treatment. Dogs fed the low dose of 
CFB also tended to have an improved PSS (-1.46; P = 0.06) and pain at its worst score (-2.14; P 
= 0.08) from day 0 to day 28 compared to dogs fed the placebo (0.05 and 0.00, respectively). All 
other CBPI scores were unaffected by treatments. Gait analysis data, namely PVF and VI, were 
not affected by treatments (Table 3.2).  
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Table 3.3 presents the inflammatory marker data for all dogs. Dogs fed the high dose of 
CFB had a greater (P = 0.05) increase in sRAGE concentration between day 0 and 28 (7.88 
ng/mL) compared to dogs fed the placebo (0.83 ng/mL). There were no treatment differences for 
the other inflammatory markers measured.  
Serum chemistry data are presented in Table 3.4. All metabolites were within reference 
range except total alkaline phosphatase and corticosteroid-induced alkaline phosphatase, which 
started and ended at higher concentrations than the upper reference range values. Dogs fed the 
high dose of CFB tended to have a greater (P = 0.07) reduction in serum chloride from day 0 to 
28 (-1.64 mmol/L) compared to dogs fed the low dose of CFB (0.08 mmol/L). No other 
treatment differences were observed for serum chemistry analysis.  
No significant differences were found for goniometry and radiograph scores after 28 days 
of treatment.  
 
Sub-Analysis of Data Collected with Large Dogs (> 23 kg) 
When only large dogs were evaluated, several CBPI scores were altered in dogs fed the 
low dose of CFB compared to dogs fed the placebo (Table 3.5). Dogs fed the low dose were 
shown to have decreased (P < 0.05) scores for the PSS (-1.77) and pain at its worst (-2.45) from 
day 0 to 28 compared to the placebo group (0.19 and 0.42, respectively). Dogs fed the low dose 
of CFB tended to have improved scores for pain at its least (-1.27; P = 0.08) and pain on average 
(-1.82; P = 0.07) compared to dogs fed the placebo (0.25 and -0.08, respectively), but no 
difference was observed for dogs fed the high dose or combination groups. From the pain 
interference questions, dogs fed the low dose (-3.09) were shown to improve (P < 0.05) in their 
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ability to rise from a lying position compared to the placebo treatment (0.25). The rest of the 
CBPI scores were unchanged by treatment.  
Gait analysis (Table 3.6), serum inflammatory markers (Table 3.7), and serum chemistry 
profiles (Table 3.8) in large dogs were not altered by treatment. 
 
DISCUSSION 
 
 As OA is an incurable disease, a combination of treatments can be used to manage the 
disease. Management strategies aim to alleviate symptoms and pain, improve joint mobility, and 
slow progression of the disease. Successful treatments depend on the severity of OA in each 
patient as well as cooperation of owners. Common strategies to alleviate symptoms include 
pharmacological intervention, administration of nutraceuticals, diet modification or weight loss, 
rehabilitation, surgery, or alternative treatments such as acupuncture or laser treatments 
(MacPhail, 2000; Rychel, 2010; Sanderson et al., 2009). With obesity being a leading risk factor 
of OA, weight management has been reported to be beneficial in alleviating some of the 
symptoms of OA, with benefits observed in dogs that reduced BW by only 6.1% (Marshall et al., 
2010). Simple rehabilitation in the form of stretching has been shown to have significant effects 
(P < 0.05) for improvement of joint range of motion (7 to 23% increase in range) in dogs 
affected by OA (Crook et al., 2007).  
Pharmacological interventions, such as NSAIDs, are the main treatment used (MacPhail, 
2000), but side effects are a concern to owners and veterinarians (Comblain et al., 2015; Rychel, 
2010). Dietary supplements or nutraceuticals are common alternatives to drug therapy. 
Chondroitin sulfate and GH are the most popular nutraceuticals for management of OA, but 
conflicting results exist for dogs. A negative-controlled study conducted by Johnson and others 
(2001) tested the effects of a supplement containing 200 mg CS, 250 mg GH, and 5 mg 
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manganese ascorbate per capsule in dogs who underwent cranial cruciate ligament transection (n 
= 16). Dogs were given 3 capsules every 12 hours for 30 days before the dose was reduced to 2 
capsules every 12 hours for the following 4 months (Johnson et al., 2001). Compared to the 
controls, dogs given the supplement had elevated concentrations of CS epitopes in synovial fluid, 
suggesting modulation of articular cartilage matrix metabolism (Johnson et al., 2001). A double-
blind, placebo-controlled study conducted using arthritic dogs (n = 7 to 10/treatment group) 
noted a reduction in observational pain overall (51%), after limb manipulation (48%), and after 
physical exertion (43%) after 150 days of supplementation of 2000 mg GH and 1600 mg CS (P < 
0.05) (Gupta et al., 2012). Another double-blind, positive-controlled study reporting positive 
effects of GH/CS in dogs (n = 35) suffering from OA tested a supplement containing the 
following active ingredients: GH (475 mg/g), CS (350 mg/g), N-acetyl-D-glucosamine (50 
mg/g), ascorbic acid (50 mg/g), and zinc sulfate (30 mg/g) (McCarthy et al., 2007). For the first 
70 days, the supplement was dosed at 1 g of active ingredients twice daily for 5 to 19.9 kg dogs, 
1.5 g of active ingredients twice daily for 20 to 40 kg dogs, and 2 g of active ingredients twice 
daily for dogs weighing > 40 kg (McCarthy et al., 2007). The dose then was reduced by 1/3 for 
the next 28 days (McCarthy et al., 2007). In the study conducted by McCarthy et al. (2007), 
improvements (P < 0.001) in overall condition score, pain on palpation, and weight-bearing from 
baseline scores were observed.  
Not all studies have shown positive effects, however. A double-blind, placebo-controlled 
study testing 22 mg CS/kg BW or 11 mg mussel extract/kg BW in 58 dogs suffering from OA 
showed no significant improvement in symptoms (Dobenecker et al., 2002). Similarly, research 
conducted on 71 OA dogs resulted in no differences in gait analysis or subjective assessment 
when treated with 3 to 4 capsules (number depended on BW; each capsule contained 500 mg 
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GH, 400 mg CS, and 75 mg manganese ascorbate) for 60 days in a placebo-controlled, double-
blind study (Moreau et al., 2003). Variation in experimental procedures among studies may 
explain the variation in results. Prior studies researching canine OA have been conducted using a 
variety of experimental designs, lengths of treatment, and animal populations and numbers. 
Along with those factors, treatments often involve multiple active ingredients with different 
doses, making it difficult to assess the efficacy of each ingredient alone. The sources and quality 
of CS and GH also may be different and contribute to the discrepancies reported in the literature 
(Calamia et al., 2012; Martel-Pelletier et al., 2015). For example, CS may be extracted from 
various animal sources, including bovine, porcine, chicken, or marine cartilage, and may differ in 
molecular composition, purity, and production processes. 
Even though nutraceuticals with the ability to alleviate symptoms of OA in the dog 
already exist, the search for other novel chondroprotective agents is of interest. This was the first 
canine clinical trial to evaluate the efficacy of CFB in alleviating clinical signs, improving joint 
motion, and decreasing inflammation associated with OA. Calcium fructoborate, a nature-
identical compound consisting of calcium, fructose, and boron, is available as a stable, 
bioavailable, water-soluble white powder developed and patented by FutureCeuticals, Inc. 
(Miljkovic, 1999).          
Previous studies researching CFB in humans have used the Western Ontario and 
McMaster Universities Arthritis Index (WOMAC) (Bellamy, 1988) and McGill Pain 
Questionnaire (MPQ) (Melzack, 1975; Melzack, 2005) to assess physical function and pain of 
human patients suffering from OA. Those surveys determine the effectiveness of an intervention 
by asking participants to answer a series of questions about their pain and hardships with 
physical movements and then scoring the questionnaires, with decreased scores representing less 
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pain and physical limitations. One study showed a 29% reduction (P < 0.01) in WOMAC score 
and a 14% reduction (P < 0.01) in MPQ score after knee OA-afflicted adult humans (n = 19; ages 
45 to 64 years; mean BMI = 28.7 kg/m2) who consumed 108 mg CFB twice a day over a 14-day 
period (Reyes-Izquierdo et al., 2012). Another 14-day study in humans with self-reported joint 
discomfort (n = 60; mean age = 49.2 years) tested CFB at a dose of 110 mg twice daily and 
showed decreased (P < 0.0001) WOMAC (-13.73) and MPQ (-8.9) scores on day 14 compared to 
baseline (Pietrzkowski et al., 2014).  
Pet owners in the current study completed the CBPI survey to assess the pain and QOL of 
their pet. In this study, including both the analysis of all dogs and the sub-analysis of large dogs, 
we observed some improvement in pain and lameness scores with CFB supplementation at the 
low dose. The reduction in pain and improved functionality reported by dog owners is in 
agreement with previous human CFB data. As dogs are unable to provide an assessment of pain, 
owners were required to complete the questionnaire for them. Even though significant 
improvements were found for individual questions, the PIS and PSS scores carry the most weight 
because the CBPI has been validated for those scores. The current study reported significant 
decreases for PSS in both the analysis of all dogs and sub-analysis of large dogs. The authors 
acknowledge that the CBPI scoring system is subjective, but believe it is a good representation 
because the same owner completed the questionnaire on each day. Decisions in regards to 
management and/or treatments will ultimately come from the owners. Therefore, improvements 
observed and reported by owners within 28 days are viewed as positive results.  
Blood inflammatory biomarkers continue to be measured as potential indicators for 
disease progression of OA. They also are targets for treatment options, as it is known that OA is 
characterized by inflammation of the joints. C-reactive protein is a common marker of 
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inflammation used to evaluate the severity of joint diseases in humans (Ohno et al., 2006). 
Previous studies in humans testing the effects of CFB on blood CRP concentrations have shown 
positive results. A 30-day study testing 112 mg CFB/day in healthy adult humans (n = 78; ages 
40 to 60 years; BMI 24 to 27 kg/m2) demonstrated a 31.3% reduction in serum CRP 
concentrations (Rogoveanu et al., 2015). The experiment conducted by Reyes-Izquierdo et al. 
(2012) on adult humans suffering from knee OA (n = 19; ages 45 to 64 years; mean BMI = 28.7 
kg/m2) reported a 37% reduction in serum CRP concentrations after 14 days of CFB 
supplementation of 216 mg/day. Also, a 15-day study in adult humans afflicted with primary OA 
(n = 60; ages 59 to 68 years) testing a treatment of 57 mg CFB/day reported decreased serum 
CRP concentrations by 60.25% (Scorei et al., 2011). In this study, no differences were reported 
in CRP concentrations among treatments. Despite its use in humans, CRP has not been validated 
as an inflammatory marker in the dog, and our results seem to support this observation (Bennett 
et al., 2013; Hurter et al., 2005). 
In the current study, inflammatory markers had fewer differences than expected. The only 
difference observed in these markers was an increased sRAGE concentration in dogs fed the high 
CFB dose compared to dogs fed the placebo. The receptor for advanced glycation end products 
(RAGE) generates reactive oxygen species and is involved in a cascade of events leading to 
inflammation and cartilage damage (Chayanupatkul and Honsawek, 2010). Serving in a 
protective role, sRAGE is a competitor of RAGE and functions by binding to similar ligands 
such as HMGB-1 and S100/calgranulins (Chayanupatkul and Honsawek, 2010; Santilli et al., 
2009). Therefore, an increase in sRAGE after treatment suggests increased binding and 
interference with RAGE, potentially leading to decreased inflammation and reduction of 
cartilage damage.  
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Goniometry and gait analysis were not different in the current study, but have been 
shown to improve in past OA studies. A study conducted on osteoarthritic Labrador Retrievers (n 
= 10; mean age = 7.5 years) resulted in a 14.6° improvement (P < 0.0005) of joint flexion in all 
dogs after 21 days of stretching (Crook et al., 2007). Previous research in OA dogs (n = 38; ages 
= 1 to 18 years) noted an increase (P = 0.01) in the gait analysis (PVF) after 90 days of feeding a 
test diet supplemented with fish oil-based omega-3 fatty acids (Roush et al., 2010b). Another 14-
day study evaluating the effects of carprofen, an NSAID, in dogs suffering from OA (n = 68; 
ages = 3 to 14 years) showed decreases for PSS and PIS (P = 0.002 and P = 0.03, respectively) 
and increases in PVF and VI (P = 0.006 and P = 0.02, respectively) compared to the placebo 
(Brown et al., 2013). Although there were significant differences, they did not show correlation 
between decreased PSS and PIS scores with an increase in PVF and VI (Brown et al., 2013).  
The lack of differences in gait analysis, goniometry, and inflammatory markers among 
treatments in this study may have been due to several factors including the dosages tested, the 
timing of dosage in relation to meal times, a short length of study, or a relatively small number of 
animals recruited and assigned to each treatment group. There was a wide variation in sizes, 
breeds, and ages of dogs as well as baseline severity of OA. All of these factors may affect the 
measurements taken and lead to increased variability. At this time, it is unclear why the low dose 
appeared to be more effective. Further studies testing different doses and/or dosing at multiple 
times per day would be beneficial. In this study, small and large dogs were given different 
dosages per day, but future studies could divide the dogs into more weight categories including a 
medium and/or giant sizes. Owners were not instructed to provide the treatment with or without 
food, so it is unclear if supplement/meal time had an effect. Human CFB studies have usually 
followed twice a day dosing protocol compared to the once a day dosing protocol used in this 
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study. It is unknown whether twice a day CFB supplementation would have led to more 
beneficial results due to an extended period of CFB exposure in the circulation and/or tissues. 
Future research on CFB use in dogs could include a dose response study to identify the most 
effective dose or determine if there is a threshold for minimum severity of OA for CFB to be 
most beneficial. It would be valuable to conduct a long-term study testing CFB, as it is possible 
that 28-days of supplementation was not long enough to see improvements in range of motion 
and gait analysis. Further experimentation exploring more inflammatory markers may identify 
the best markers for progression of the disease in the dog. Studies that examine the long-term 
efficacy and safety of CFB for use in canine OA also may also be beneficial.  
 
CONCLUSION 
 
In conclusion, the results of this randomized, double-blinded, placebo-controlled clinical 
trial showed that CFB is associated with some mitigation of joint pain and improved mobility in 
the dog over a 28-day period. The CBPI, a validated survey, provided a good indication that 
owners observed a difference in their dog’s behavior with CFB treatment. As this was the first 
study testing CFB supplementation in dogs, further experimentation with a larger sample size 
and over a longer time period should be conducted to confirm the effectiveness of CFB on 
alleviating symptoms associated with OA. 
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TABLES AND FIGURES 
 
Table 3.1. Canine brief pain inventory scores for all dogs expressed as the difference between data collected on day 
28 and day 0 
Variable Placebo1 Low Dose2 High Dose3 Combination4 SEM P-Value 
Pain at its worst* 0.00x -2.14y -0.43xy -0.53xy 0.593 0.08 
Pain at its least* 0.33 -0.93 -0.64 0.03 0.379 0.08 
Pain on average* -0.27 -1.43 -0.57 -0.78 0.427 0.29 
Pain as of right now* 0.13 -1.36 -1.14 -0.37 0.460 0.09 
Interference of general activity* -1.27 -1.79 -1.36 -0.69 0.466 0.42 
Interference of enjoyment of life* -0.80 -1.86 -1.00 -1.00 0.568 0.58 
Interference with the ability to rise 
from a lying position* 
0.00a -2.93b -2.21b -1.38ab 0.558 <0.01 
Interference with the ability to walk* 0.00 -1.43 -1.36 -1.25 0.534 0.20 
Interference with the ability to run* -0.87 -1.64 -0.57 -1.31 0.614 0.63 
Interference with the ability to climb 
up* 
-0.40 -2.21 -1.57 -1.44 0.520 0.12 
Overall quality of life+ 0.20 0.14 0.21 0.47 0.165 0.50 
Pain severity score (PSS)± 0.05x -1.46y -0.70xy -0.41xy 0.388 0.06 
Pain interference score (PIS)† -0.56 -1.98 -1.35 -1.18 0.393 0.10 
abMean values in the same row with unlike superscript letters differ (P < 0.05). 
xyMean values in the same row with unlike superscript letters differ (P < 0.10). 
1Placebo contained 60 mg of fructose. 
2Low dose contained 69 mg of calcium fructoborate (CFB). 
3High dose contained 127 mg of CFB. 
4Combination contained 69 mg CFB, 500 mg glucosamine hydrochloride, and 200 mg chondroitin sulfate. 
*Questions were scored on a scale of 0 to 10, with 0 representing no pain/interference and 10 representing extreme 
pain/interference. 
+Question was answered with qualitative answers ranging from poor to excellent. 
±PSS is the average of 4 questions rating the dog’s pain intensity in the last 7 days. 
†PIS is the average of 6 questions rating how much the dog’s pain interferes with its normal activity. 
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Table 3.2. Gait analysis values for all dogs expressed as the difference between data collected on day 28 and day 0 
Variable Placebo1 Low Dose2 High Dose3 Combination4 SEM P-Value 
Peak vertical force (N/m)* 37.94 13.28 -52.68 -4.52 34.50 0.32 
Vertical impulse (s) 0.00 0.11 0.04 -0.01 0.160 0.95 
*N/m as a % of body weight. 
1Placebo contained 60 mg of fructose. 
2Low dose contained 69 mg of calcium fructoborate (CFB). 
3High dose contained 127 mg of CFB. 
4Combination contained 69 mg CFB, 500 mg glucosamine hydrochloride, and 200 mg chondroitin sulfate. 
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Table 3.3. Serum inflammatory marker concentrations for all dogs expressed as the difference between data 
collected on day 28 and day 0 
Variable Placebo1 Low Dose2 High Dose3 Combination4 SEM P-Value 
Cartilage oligomeric matrix 
protein (ng/mL) 
-0.68 -2.71 -1.55 -3.66 1.036 0.60 
C-reactive protein (ng/mL) -308.60 -168.38 159.36 904.50 563.708 0.39 
Matrix metalloproteinase 3 
(ng/mL) 
-0.03 -0.15 0.09 0.04 0.228 0.90 
Follistatin-like protein-1 (ng/mL) -12.79 -21.71 -8.28 -16.20 145.391 0.83 
C-terminal cross-linked 
telopeptide type II collagen 
(ng/mL) 
-0.03 0.99 -0.03 0.10 0.463 0.38 
Hyaluronan (ng/mL) 3.87 -1.48 -3.29 0.21 6.120 0.86 
Col2-3/4C (long mono) (ng/mL) 0.18 -1.18 1.58 1.03 1.329 0.22 
Soluble receptor for advanced 
glycation end products (ng/mL) 
0.83y 12.33xy 7.88x 9.92xy 3.429 0.05 
Chitinase 3-like protein 1 (ng/mL) -4.95 -4.50 -9.15 -3.46 2.868 0.24 
Interleukin 6 (pg/mL) -2.16 -3.27 -0.19 -1.20 2.381 0.83 
xyMean values in the same row with unlike superscript letters differ (P < 0.10). 
1Placebo contained 60 mg of fructose. 
2Low dose contained 69 mg of calcium fructoborate (CFB). 
3High dose contained 127 mg of CFB. 
4Combination contained 69 mg CFB, 500 mg glucosamine hydrochloride, and 200 mg chondroitin sulfate.  
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Table 3.4. Serum chemistry values for all dogs expressed as the difference between data collected on day 28 and 
day 0 
Variable Placebo1 Low Dose2 High Dose3 Combination4 SEM P-Value 
Creatinine (mg/dL) -0.03 0.01 -0.02 0.02 0.023 0.43 
Blood urea nitrogen (mg/dL) -2.47 -0.43 -0.79 0.44 1.031 0.24 
Total protein (g/dL) -0.05 -0.04 -0.03 0.06 0.054 0.49 
Albumin (g/dL) -0.05 -0.01 -0.06 0.01 0.037 0.56 
Globulin (g/dL) 0.00 -0.03 0.03 0.05 0.044 0.60 
Albumin: globulin 0.00 0.01 -0.04 0.01 0.023 0.51 
Calcium (mg/dL) -0.01 0.09 -0.04 0.08 0.090 0.69 
Phosphorous (mg/dL) -0.01 0.04 0.16 0.09 0.194 0.94 
Sodium (mmol/L) -0.53 0.14 -1.21 -0.56 0.561 0.43 
Potassium (mmol/L) 0.12 0.16 0.03 0.13 0.061 0.50 
Sodium: potassium -0.73 -1.00 -1.29 -0.88 0.520 0.90 
Chloride (mmol/L) -0.67xy 0.08x -1.64y -0.94xy 0.435 0.07 
Glucose (mg/dL) 0.60 -0.57 -3.14 -1.50 4.064 0.93 
Total alkaline phosphatase (ALP) 
(U/L) 
4.07 8.00 -3.50 2.79 3.788 0.21 
Corticosteroid-induced ALP (U/L) 1.07 3.31 0.79 -0.36 2.307 0.64 
Alanine aminotransferase (U/L) -0.60 -0.86 3.00 -2.93 3.868 0.45 
Gamma-glutamyltransferase (U/L) -0.13 -0.21 0.00 0.25 0.423 0.87 
Total bilirubin (mg/dL) 0.01 -0.01 0.02 -0.01 0.018 0.67 
Cholesterol (mg/dL) -4.38 4.62 2.62 5.60 5.307 0.55 
Triglycerides (mg/dL) 8.55 4.64 5.75 2.87 6.369 0.93 
Bicarbonate (mmol/L) 0.13 0.14 1.14 1.00 0.508 0.35 
xyMean values in the same row with unlike superscript letters differ (P < 0.10). 
1Placebo contained 60 mg of fructose. 
2Low dose contained 69 mg of calcium fructoborate (CFB). 
3High dose contained 127 mg of CFB. 
4Combination contained 69 mg CFB, 500 mg glucosamine hydrochloride, and 200 mg chondroitin sulfate.  
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Table 3.5. Canine brief pain inventory scores for large dogs expressed as the difference between data collected on 
day 28 and day 0 
Variable Placebo1 Low Dose2 High Dose3 Combination4 SEM P-Value 
Pain at its worst* 0.42a -2.45b -0.09ab -0.62ab 0.668 0.02 
Pain at its least* 0.25x -1.27y -0.36xy 0.00xy 0.424 0.08 
Pain on average* -0.08x -1.82y -0.27xy -0.92xy 0.486 0.07 
Pain as of right now* 0.17 -1.55 -0.82 -0.50 0.508 0.14 
Interference of general activity* -1.17 -2.00 -1.36 -0.85 0.552 0.52 
Interference of enjoyment of life* -0.75 -2.00 -0.73 -1.31 0.685 0.54 
Interference with the ability to rise 
from a lying position* 
0.25a -3.09b  -2.09ab -1.62ab 0.615 <0.01 
Interference with the ability to walk* -0.42 -1.45 -1.00 -1.00 0.589 0.68 
Interference with the ability to run* -1.17 -1.64 0.00 -1.15 0.689 0.42 
Interference with the ability to climb 
up* 
-0.58 -2.18 -1.36 -1.46 0.604 0.34 
Overall quality of life+ 0.08 0.18 0.09 0.50 0.180 0.30 
Pain severity score (PSS) ± 0.19a -1.77b -0.39ab -0.50ab 0.427 0.02 
Pain interference score (PIS) † -0.64 -2.06 -1.09 -1.23 0.442 0.17 
abMean values in the same row with unlike superscript letters differ (P < 0.05). 
xyMean values in the same row with unlike superscript letters differ (P < 0.10). 
1Placebo contained 60 mg of fructose. 
2Low dose contained 69 mg of calcium fructoborate (CFB). 
3High dose contained 127 mg of CFB. 
4Combination contained 69 mg CFB, 500 mg glucosamine hydrochloride, and 200 mg chondroitin sulfate.  
*Questions were scored on a scale of 0 to 10, with 0 representing no pain/interference and 10 representing extreme 
pain/interference. 
+Question was answered with qualitative answers ranging from poor to excellent. 
±PSS is the average of 4 questions rating the dog’s pain intensity in the last 7 days.  
†PIS is the average of 6 questions rating how much the dog’s pain interferes with its normal activity.  
  
  46 
 
Table 3.6. Gait analysis values for large dogs expressed as the difference between data collected on day 28 and day 
0 
Variable Placebo1 Low Dose2 High Dose3 Combination4 SEM P-Value 
Peak vertical force (N/m)* 61.29 16.49 -45.97 -20.14 3.911 0.24 
Vertical impulse (s) -0.12 0.12 0.00 -0.09 0.175 0.77 
*N/m as a % of body weight. 
1Placebo contained 60 mg of fructose. 
2Low dose contained 69 mg of calcium fructoborate (CFB). 
3High dose contained 127 mg of CFB. 
4Combination contained 69 mg CFB, 500 mg glucosamine hydrochloride, and 200 mg chondroitin sulfate. 
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Table 3.7. Serum inflammatory marker concentrations for large dogs expressed as the difference between data 
collected on day 28 and day 0 
Variable Placebo1 Low Dose2 High Dose3 Combination4 SEM P-Value 
Cartilage oligomeric matrix 
protein (ng/mL) 
-0.54 -3.13 -1.78 -4.68 1.269 0.29 
C-reactive protein (ng/mL) 74.17 -239.00 408.55 1130.69 684.483 0.13 
Matrix metalloproteinase 3 
(ng/mL) 
-0.04 -0.24 0.00 -0.02 0.272 0.93 
Follistatin-like protein-1 (ng/mL) -14.28 -25.41 -9.13 -19.29 7.911 0.97 
C-terminal cross-linked 
telopeptide type II collagen 
(ng/mL) 
0.00 0.93 -0.18 -0.48 0.536 0.33 
Hyaluronan (ng/mL) -2.26 -4.22 -2.99 -4.61 6.243 0.99 
Col2-3/4C (long mono) (ng/mL) -0.12 -2.07 1.66 0.14 1.586 0.31 
Soluble receptor for advanced 
glycation end products (ng/mL) 
1.85 13.99 8.77 11.99 4.140 0.19 
Chitinase 3-like protein 1 (ng/mL) -5.44 -4.82 -3.72 -3.01 2.154 0.38 
Interleukin 6 (pg/mL) -1.20 -3.07 -0.83 -1.70 1.882 0.87 
1Placebo contained 60 mg of fructose. 
2Low dose contained 69 mg of calcium fructoborate (CFB). 
3High dose contained 127 mg of CFB. 
4Combination contained 69 mg CFB, 500 mg glucosamine hydrochloride, and 200 mg chondroitin sulfate. 
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Table 3.8. Serum chemistry values for large dogs expressed as the difference between data collected on day 28 and 
day 0  
Variable Placebo1 Low Dose2 High Dose3 Combination4 SEM P-Value 
Creatinine (mg/dL) -0.03 0.02 -0.03 0.02 0.027 0.38 
Blood urea nitrogen (mg/dL) -2.50 -1.09 -0.73 1.23 1.220 0.18 
Total protein (g/dL) -0.04 -0.03 -0.04 0.07 0.060 0.49 
Albumin (g/dL) -0.04 0.00 -0.07 0.02 0.041 0.43 
Globulin (g/dL) 0.00 -0.03 0.04 0.05 0.049 0.65 
Albumin: globulin 0.01 0.00 -0.05 0.02 0.024 0.30 
Calcium (mg/dL) 0.00 0.14 0.04 0.06 0.072 0.60 
Phosphorous (mg/dL) -0.01 -0.10 0.16 0.14 0.221 0.82 
Sodium (mmol/L) -0.67 -0.09 -1.00 -0.23 0.619 0.73 
Potassium (mmol/L) 0.14 0.14 0.06 0.13 0.066 0.83 
Sodium: potassium -1.00 -1.00 -0.91 -0.92 0.537 0.10 
Chloride (mmol/L) -0.83 0.00 -1.73 -0.69 0.479 0.13 
Glucose (mg/dL) 1.42 -3.82 -1.45 -4.85 4.404 0.74 
Total alkaline phosphatase (ALP) 
(U/L) 
5.00 2.91 -1.18 -1.67 5.825 0.53 
Corticosteroid-induced ALP (U/L) 1.17 5.70 1.64 -3.92 3.269 0.57 
Alanine aminotransferase (U/L) 0.42 -6.90 -1.90 -4.58 3.362 0.45 
Gamma-glutamyltransferase (U/L) 0.08 -0.73 0.09 0.62 0.410 0.16 
Total bilirubin (mg/dL) 0.00 0.01 0.00 -0.02 0.018 0.91 
Cholesterol (mg/dL) -5.80 4.10 3.70 9.67 6.204 0.36 
Triglycerides (mg/dL) 19.36 -1.55 -15.90 4.77 
12.28
6 
0.35 
Bicarbonate (mmol/L) 0.00 0.09 1.45 1.08 0.567 0.21 
1Placebo contained 60 mg of fructose. 
2Low dose contained 69 mg of calcium fructoborate (CFB). 
3High dose contained 127 mg of CFB. 
4Combination contained 69 mg CFB, 500 mg glucosamine hydrochloride, and 200 mg chondroitin sulfate. 
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Figure 3.1. Classification of diets collected from the 59 dogs completing the study 
 
  
36
7
5
1
10
0
10
20
30
40
50
60
Non-clinical Diets Clinical Diets
Diet Classifications
Clinical diets
Healthy mobility
Senior
Weight management
Other
  50 
 
Figure 3.2. Percentage of clinical diet claims of the diets collected from the 59 dogs completing 
the study 
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Figure 3.3. Exercise duration data from the 59 dogs completing the study 
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